Gyre Therapeutics (GYRE) Short-term Investments (2010 - 2026)
Gyre Therapeutics (GYRE) posted quarterly Short-term Investments of $12.3 million for Q1 2026, down 16.89% year-over-year from $14.8 million in Q1 2025, and down 20.13% quarter-over-quarter from $15.4 million in Q4 2025.
Gyre Therapeutics (GYRE) Short-term Investments (2010 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Short-term Investments for 15 consecutive years, with $12.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Short-term Investments fell 16.89% year-over-year to $12.3 million; the TTM figure through Mar 2026 stood at $12.3 million (down 16.89% YoY), while the FY2025 annual figure was $15.4 million, up 3.65% from the prior year.
- Short-term Investments declined to $12.3 million in Q1 2026 per GYRE's latest filing, from $15.4 million in the prior quarter.
- Across five years, Short-term Investments topped out at $19.6 million in Q3 2025 and bottomed at $7.6 million in Q1 2024.
- Historically, Short-term Investments has averaged $13.4 million across 3 years, with a median of $14.8 million in 2025.
- Annual changes were most pronounced in 2025 — Short-term Investments surged 112.44% — and 2026, when it retreated 16.89%.
- Gyre Therapeutics' Short-term Investments stood at $14.9 million in 2024, then increased by 3.65% to $15.4 million in 2025, then slipped by 20.13% to $12.3 million in 2026.
- Business Quant data shows GYRE's Short-term Investments at $12.3 million in Q1 2026, $15.4 million in Q4 2025, and $19.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Gyre Therapeutics | 708.31 Mn | 685.47 Mn | 26.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14.10 Mn |
| Mar 31, 2026 | 12.30 Mn |
| Dec 31, 2025 | 15.40 Mn |
| Sep 30, 2025 | 19.60 Mn |
| Jun 30, 2025 | 17.87 Mn |
| Mar 31, 2025 | 14.80 Mn |
| Dec 31, 2024 | 14.86 Mn |
| Sep 30, 2024 | 9.23 Mn |
| Jun 30, 2024 | 9.00 Mn |
| Mar 31, 2024 | 7.57 Mn |
| Dec 31, 2021 | 2.50 Mn |
| Sep 30, 2021 | 5.37 Mn |
| Jun 30, 2021 | 12.90 Mn |
| Mar 31, 2021 | 23.96 Mn |
| Dec 31, 2020 | 48.99 Mn |
| Sep 30, 2020 | 77.96 Mn |
| Jun 30, 2020 | 58.09 Mn |
| Mar 31, 2020 | 34.16 Mn |
| Dec 31, 2019 | 61.50 Mn |
| Sep 30, 2019 | 61.93 Mn |